Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.52 |
| ▸ | P2RY10 | O00398 | 11/20 | 0.46 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957361 | 1.00 | PLA2G2C (0.52) | PLA2G2CP2RY10GPR34GPR174FABP3 | |
| SCHEMBL5968303 | 0.93 | P2RY10 (0.52) | P2RY10GPR34GPR174 | |
| SCHEMBL2011436 | 0.93 | P2RY10 (0.52) | P2RY10GPR34GPR174 | |
| SCHEMBL4752181 | 0.83 | ENPP2 (0.56) | — | |
| Phosphorylethanolamine SCHEMBL993264 | 0.83 | LPAR3 (0.44) | PLA2G2C | |
| Phosphorylethanolamine SCHEMBL19412013 | 0.81 | LPAR3 (0.42) | PLA2G2C | |
| SCHEMBL10594311 | 0.80 | PLA2G2C (0.50) | PLA2G2CP2RY10GPR34 | |
| SCHEMBL226745 | 0.77 | PLA2G2C (0.43) | PLA2G2CP2RY10GPR34GPR174 | |
| SCHEMBL3963403 | 0.77 | PLA2G2C (0.43) | PLA2G2CP2RY10GPR34GPR174 | |
| SCHEMBL19410782 | 0.77 | PLA2G2C (0.43) | PLA2G2CP2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367638-A1 | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS | BYERS CRYSTAL (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367638-A1 | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS | ADIPOR1, IGF2BP1, LRBA | PLA2G2C 2709/4885P2RY10 4545/4885GPR34 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.